OGT, a global provider of genomic research and diagnostic solutions, has launched the RNA-based SureSeq Myeloid Fusion Panel, a novel next-generation sequencing (NGS) tool for identifying key fusion genes implicated in acute myeloid leukaemia (AML).
Designed in collaboration with myeloid cancer experts, the SureSeq Myeloid Fusion Panel ensures results meet the latest clinical research recommendations by efficiently identifying over 30 key disease-associated fusions in AML —including KMT2A and MECOM fusions — in a single assay.
By utilising a partner-gene agnostic approach, fusions with multiple partners as well as novel and rare fusions can be identified, expanding the ability to classify samples.
This panel is fully compatible with the company’s existing end-to-end Universal NGS Complete Workflow Solution and complimentary data analysis software to minimise hands-on time and provide easy analysis without the need for additional bioinformatics resource.
“Our experience with genetic technologies, combined with insights from leading myeloid cancer experts, has allowed us to develop a valuable tool for myeloid research, supported by a highly efficient workflow. This will enable users to confidently and rapidly detect the most relevant fusion genes in a single assay.” Said Adrian Smith, CEO of OGT.
